Table 2.
Clinical and biologic data at the time of kidney biopsy
| Characteristics | Number |
|---|---|
| AKI according KDIGO criteria, n=23 | |
| Stage 1 | 1 (4%) |
| Stage 2 | 2 (9%) |
| Stage 3 | 20 (87%) |
| Hypertension, n=23 | 10 (43%) |
| uPCR, g/g, n=21/23a | 9.49 (range, 1.7–27) |
| Serum albumin level, g/dl, n=21/23 | 2.0 (range, 0.7–4) |
| Microscopic hematuria, n=21/23a | 10 (48%) |
| Leukocyturia, n=21/23a | 9 (43%) |
| Time between malaria infection and kidney biopsy, d, n=23 | 24 d (range, 7–80) |
| Immunologic findings, n=23 | |
| None | 20 (87%) |
| IgGκ spike | 1 (4%) |
| Cryo (type II) | 2 (9%) |
| Parvovirus B19 serology, n=14/23 | |
| IgM+, IgG− | 4 (29%) |
| IgM−, IgG+ | 0 (0%) |
| IgM+, IgG+ | 0 (0%) |
| IgM−, IgG− | 10 (71%) |
| ApoL1 status, n=7/23 | |
| G1/G1 | 4 (57%) |
| G1/G2 | 3 (43%) |
KDIGO, Kidney Disease Improving Global Outcome; uPCR, urine protein-creatinine ratio; Cryo, cryoglobulinemia.
a
Two patients with anuria.